TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer



Status:Completed
Conditions:Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/16/2016
Start Date:November 2010
End Date:December 2016

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is
superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or
resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

AMG 386 is a man-made medication that is designed to stop the development of blood vessels
in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process
called angiogenesis, to obtain a supply of oxygen and nutrients to grow.


Inclusion Criteria:

- Female 18 years of age or older at the time the written informed consent is obtained

- Gynecologic Oncology Group (GOG) Performance Status of 0 or 1

- Life expectancy >= 3 months (per investigator opinion)

- Histologically or cytologically documented invasive epithelial ovarian cancer,
primary peritoneal cancer, or fallopian tube cancer (Subjects with pseudomyxoma ,
mesothelioma, unknown primary tumor, sarcoma, or neuroendocrine histology, with
borderline ovarian cancer, ie, subjects with low malignant potential tumors, and with
clear cell or mucinous histology are excluded)

- Subjects must have undergone surgery for ovarian cancer, primary peritoneal cancer,
or fallopian tube cancer including at least a unilateral oophorectomy

- Radiologically evaluable disease per Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 with modifications

- Subjects must have had one prior platinum-based chemotherapeutic regimen for
management of primary disease containing carboplatin, cisplatin, or another
organoplatinum compound. This initial treatment may have included intraperitoneal
therapy, high-dose therapy, consolidation therapy, bevacizumab or extended therapy
administered after surgical or non-surgical assessment.

- Adequate organ and hematological function

- Generally well controlled blood pressure with systolic blood pressure <= 140 mmHg and
diastolic blood pressure <= 90 mmHg prior to randomization. The use of
anti-hypertensive medications to control hypertension is permitted

- Radiographically documented disease progression either on or following the last dose
of prior chemotherapy regimen for epithelial ovarian cancer, primary peritoneal
cancer, or fallopian tube cancer

Exclusion Criteria:

- Subjects who have received more than 3 previous regimens of anti-cancer therapy for
epithelial ovarian, primary peritoneal or fallopian tube cancers

- Subjects who have received paclitaxel as consolidation therapy, maintenance, or
monotherapy are excluded

- Subjects with primary platinum-refractory disease

- Subjects with platinum-free interval (PFI) > 12 months from their last platinum based
therapy

- Radiotherapy <= 14 days prior to randomization. Subjects must have recovered from all
radiotherapy-related toxicities

- Previous abdominal or pelvic radiotherapy

- History of arterial or venous thromboembolism within 12 months prior to randomization

- History of clinically significant bleeding within 6 months prior to randomization

- History of central nervous system metastasis

- Has not yet completed a 21 day washout period prior to randomization for any previous
anti cancer systemic therapies (30 days for prior bevacizumab)

- Enrolled in or has not yet completed at least 30 days (prior to randomization) since
ending other investigational device or drug, or currently receiving other
investigational treatments

- Unresolved toxicities from prior systemic therapy that are Common Terminology
Criteria for Adverse Events (CTCAE) Version 3.0 >= Grade 2 in severity except
alopecia

- Known active or ongoing infection (except uncomplicated urinary tract infection
[UTI]) within 14 days prior to randomization

- Currently or previously treated with AMG 386, or other molecules that inhibit the
angiopoietins or Tie2 receptor

- Treatment within 30 days prior to randomization with strong immune modulators
including but not limited to systemic cyclosporine, tacrolimus, sirolimus,
mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, and
lenalidomide

- Clinically significant cardiovascular disease within 12 months prior to randomization

- Major surgery within 28 days prior to randomization or still recovering from prior
surgery

- Minor surgical procedures, except placement of tunneled central venous access device
within 3 days prior to randomization. Diagnostic laparoscopy is regarded as a minor
surgical procedure.
We found this trial at
30
sites
?
mi
from
Abington, PA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boise, ID
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Brightwaters, NY
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
?
mi
from
Danbury, CT
Click here to add this to my saved trials
?
mi
from
Englewood, CO
Click here to add this to my saved trials
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Metairie, LA
Click here to add this to my saved trials
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New Lambton Heights, New South Wales 2305
?
mi
from
New Lambton Heights,
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Ogden, UT
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Peoria, IL
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Skokie, IL
Click here to add this to my saved trials
?
mi
from
Stanford, CA
Click here to add this to my saved trials
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Winston Salem, North Carolina 27157
?
mi
from
Winston Salem, NC
Click here to add this to my saved trials